Consensus AbbVie Inc. London S.E.

Stocks

0QCV

US00287Y1091

Pharmaceuticals

Delayed London S.E. 04:00:04 2026-10-08 EDT			5-day change	1st Jan Change
270.50 ^USD	-0.73%		+2.67%	+17.54%

10-07	AbbVie Shares Rise After FDA Gives 2 Breakthrough Designations for Cancer Drug	MT
10-07	AbbVie Says Telisotuzumab Adizutecan Receives Two US FDA Breakthrough Therapy Designations to Treat Colorectal Cancer, Lung Cancer	MT

df2280c7afbc4323837e6b7fc54d0.3MaWC0YCLONIorACaMyfNx7XkHy_ybCH7KthlzDATrk.t5L-MhVteaEZweRzGb3ec1mi0zHsp4fxqvxW8h2uBuqRl9RqLUUfsR7V9Q~895bead78fddfd67213e011781891f4a

Analysts' recommendations: AbbVie Inc.

10-07	Morgan Stanley Adjusts Price Target on AbbVie to $310 From $296	MT
10-06	AbbVie's Epkinly Could Be Preferred Frontline DLBCL Agent, UBS Says	MT
10-06	Scotiabank Adjusts Price Target on AbbVie to $320 From $280, Maintains Sector Outperform Rating	MT
09-29	AbbVie Shows Pipeline-Driven Upside Beyond Core Immunology Franchise, BofA Says	MT
09-29	BofA Securities Adjusts AbbVie Price Target to $289 From $282, Maintains Buy Rating	MT
09-24	Oruka Therapeutics' Psoriasis Treatment Maintains 'Competitive Profile' After Positive Clinical Data, UBS Says	MT
09-10	HSBC Adjusts Price Target on AbbVie to $315 From $300, Keeps Buy Rating	MT
09-08	BofA Securities Adjusts Price Target on AbbVie to $282 From $276	MT
08-20	Piper Sandler Adjusts Price Target on AbbVie to $303 From $298, Maintains Overweight Rating	MT
08-17	Wells Fargo Adjusts Price Target on AbbVie to $300 From $295, Keeps Overweight Rating	MT
08-13	Wolfe Upgrades AbbVie to Outperform From Peer Perform, Price Target is $300	MT
08-11	BNP Paribas Adjusts Price Target on AbbVie to $247 From $218, Maintains Neutral Rating	MT
08-05	Argus Lifts AbbVie Price Target to $270 From $250	MT
08-05	Leerink Partners Adjusts Price Target on AbbVie to $279 From $245	MT
08-04	Guggenheim Adjusts Price Target on AbbVie to $288 From $261, Maintains Buy Rating	MT
08-04	Rothschild & Co Redburn Adjusts Price Target on AbbVie to $285 From $284, Maintains Buy Rating	MT
08-03	AbbVie Pipeline Draws Greater Investor Focus After 'Strong' Q2, RBC Says	MT
08-03	Oppenheimer Adjusts AbbVie Price Target to $258 From $244, Maintains Neutral Rating	MT
08-03	Canaccord Genuity Adjusts AbbVie Price Target to $290 From $282, Maintains Buy Rating	MT
07-31	JPMorgan Adjusts Price Target on AbbVie to $285 From $280	MT
07-28	Barclays Adjusts AbbVie PT to $300 From $275, Maintains Overweight Rating	MT
07-22	Canaccord Genuity Adjusts Price Target on AbbVie to $282 From $273, Maintains Buy Rating	MT
07-15	Citigroup Adjusts Price Target on AbbVie to $260 From $230, Maintains Neutral Rating	MT
07-13	BMO Capital Adjusts Price Target on AbbVie to $300 From $258, Maintains Outperform Rating	MT
07-13	UBS Adjusts Price Target on AbbVie to $260 From $230, Maintains Neutral Rating	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ELI LILLY AND COMPANY					+11.82%
	JOHNSON & JOHNSON					+8.2%
	ABBVIE INC.					+3.47%
	MERCK & CO., INC.					+9.45%
	ROCHE HOLDING AG					+4.35%
	NOVARTIS AG					+4.69%
	ASTRAZENECA PLC					+30.29%
	AMGEN INC.					-5.23%
	GILEAD SCIENCES, INC.					+8.46%
	Average					+8.39%
	Weighted average by Cap.					+8.80%